A Pilot Trial of Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

NCT01189643 EARLY_PHASE1 ACTIVE_NOT_RECRUITING

This study adds irinotecan, temozolomide and bevacizumab to the chemotherapy regimen currently used to treat Desmoplastic small round cell tumor (DSRCT). The investigators are doing this study to find out what effects, good and/or bad, the combination of irinotecan, temozolomide and bevacizumab has on the patient and the DSRCT cancer.

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	EARLY_PHASE1
Status	ACTIVE_NOT_RECRUITING
Enrolment	15
Start date	2010-08
Completion	2026-08

Conditions

• Sarcoma
• Desmoplastic Small Round Cell Tumor (DSRCT)

Interventions

• irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator

Primary outcomes

• To define the tolerability — 2 years
  of irinotecan, temozolomide and bevacizumab in patients with newly diagnosed DSRCT
• To define adverse event profile — 2 years
  of irinotecan, temozolomide and bevacizumab in patients with newly diagnosed DSRCT

Countries

United States